Get the Stockscreener App
19.87
4.25%
0.81
After Hours:
19.87
Oculis Holding Ag stock is traded at $19.87, with a volume of 79,020.
It is up +4.25% in the last 24 hours and up +15.19% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$19.06
Open:
$19.5
24h Volume:
79,020
Relative Volume:
4.07
Market Cap:
$867.57M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-9.9564
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
+14.20%
1M Performance:
+15.19%
6M Performance:
+34.26%
1Y Performance:
+31.59%
1-Day Range:
$19.35
$19.95
1-Week Range:
$17.26
$19.95
52-Week Range:
$14.00
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
19.87 | 997.52M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Chardan Research Adjusts Oculis Holding AG Price Target to $51 From $33, Maintains Buy Rating - MarketScreener
Oculis (NASDAQ:OCS) Price Target Raised to $51.00 - MarketBeat
HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price - Defense World
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Oculis (NASDAQ:OCS) Given New $36.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
Oculis stock price target raised to $36 from $33 at H.C. Wainwright - Investing.com
Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION - Ophthalmology Times
Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology - TipRanks
Does Oculis Holding AG Equity Warrant show high probability of reboundJuly 2025 Rallies & Community Supported Trade Ideas - newser.com
Reversal indicators forming on Oculis Holding AG Equity Warrant stockEarnings Risk Summary & Weekly High Conviction Trade Ideas - newser.com
Oculis Advances Privosegtor Into Registrational Trials for Neuroprotective Therapy - MarketScreener
Will Oculis Holding AG Equity Warrant bounce back from current supportJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Why retail traders accumulate Oculis Holding AG (CR5) stockJuly 2025 Review & Weekly Breakout Watchlists - newser.com
Can trapped investors hope for a rebound in Oculis Holding AG Equity WarrantJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
Oculis Advances Privosegtor into Pivotal Development for Acute Optic Neuritis and NAION Following Positive FDA Meeting - Quiver Quantitative
Will Oculis Holding AG (CR5) stock sustain bullish trend into 2025Trade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
3 pivotal trials: Oculis launches PIONEER program for Privosegtor after positive FDA meeting - Stock Titan
Oculis Holding AG Equity Warrant stock momentum explainedBond Market & Weekly Chart Analysis and Trade Guides - newser.com
Will Oculis Holding AG (CR5) stock benefit from sector leadershipMarket Growth Summary & Safe Capital Investment Plans - newser.com
Brokerages Set Oculis Holding AG (NASDAQ:OCS) PT at $35.75 - Defense World
What machine learning models say about Oculis Holding AG2025 Top Gainers & Free High Return Stock Watch Alerts - newser.com
Published on: 2025-10-05 06:40:04 - newser.com
Why Oculis Holding AG (CR5) stock is favored by hedge fundsMarket Trend Summary & Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-05 05:35:30 - newser.com
Will Oculis Holding AG rebound enough to break evenGap Down & Daily Risk Controlled Trade Plans - newser.com
Applying chart zones and confluence areas to Oculis Holding AG Equity WarrantPortfolio Gains Summary & Daily Growth Stock Investment Tips - newser.com
Multi factor analysis applied to Oculis Holding AGMarket Sentiment Review & Risk Controlled Daily Trade Plans - newser.com
Sentiment analysis tools applied to Oculis Holding AGSwing Trade & Fast Momentum Stock Entry Tips - newser.com
Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
What recovery options are there for Oculis Holding AG Equity WarrantJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Identifying reversal signals in Oculis Holding AG Equity WarrantWeekly Stock Analysis & Free Safe Capital Growth Stock Tips - newser.com
What analysts say about Oculis Holding AG Equity Warrant stockPrice-to-Book Ratio Updates & Outstanding Investment Portfolio - earlytimes.in
Will Rising Interest Rates Hurt Organic Recycling Systems Limiteds Profit MarginsGeopolitical Risk Analysis & Smart Trading Plans for Every Investor Type - earlytimes.in
What drives Oculis Holding AG Equity Warrant stock priceREITs Market Trends & Get Tomorrow’s Winners Today With AI - earlytimes.in
Can Oculis Holding AG Equity Warrant stock sustain free cash flow growthJuly 2025 Earnings & Reliable Entry Point Alerts - newser.com
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):